Ani Pharmaceuticals [ANIP] vs Zoetis [ZTS] Detailed Stock Comparison
Ani Pharmaceuticals
NASDAQ
Loading...
Zoetis
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Ani Pharmaceuticals wins in 8 metrics, Zoetis wins in 11 metrics, with 0 ties. Zoetis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ani Pharmaceuticals | Zoetis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 51.63 | 25.36 | Zoetis |
| Price-to-Book Ratio | 4.03 | 13.14 | Ani Pharmaceuticals |
| Debt-to-Equity Ratio | 136.10 | 137.01 | Ani Pharmaceuticals |
| PEG Ratio | -0.14 | 23.24 | Ani Pharmaceuticals |
| EV/EBITDA | 20.97 | 17.91 | Zoetis |
| Profit Margin (TTM) | -1.37% | 27.83% | Zoetis |
| Operating Margin (TTM) | 7.18% | 40.20% | Zoetis |
| EBITDA Margin (TTM) | 7.18% | 40.20% | Zoetis |
| Return on Equity | -2.17% | 52.77% | Zoetis |
| Return on Assets (TTM) | 1.09% | 15.37% | Zoetis |
| Free Cash Flow (TTM) | $47.06M | $2.30B | Zoetis |
| Dividend Yield | N/A | 1.11% | N/A |
| 1-Year Return | 46.08% | -16.11% | Ani Pharmaceuticals |
| Price-to-Sales Ratio (TTM) | 2.54 | 6.96 | Ani Pharmaceuticals |
| Enterprise Value | $2.19B | $70.67B | Zoetis |
| EV/Revenue Ratio | 2.93 | 7.53 | Ani Pharmaceuticals |
| Gross Profit Margin (TTM) | 64.70% | 73.62% | Zoetis |
| Revenue per Share (TTM) | $38 | $21 | Ani Pharmaceuticals |
| Earnings per Share (Diluted) | $-0.69 | $5.81 | Zoetis |
| Beta (Stock Volatility) | 0.61 | 0.88 | Ani Pharmaceuticals |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Ani Pharmaceuticals vs Zoetis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ani Pharmaceuticals | 0.54% | 1.97% | 37.72% | 49.73% | 50.16% | 62.48% |
| Zoetis | 1.51% | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ani Pharmaceuticals | 46.08% | 137.11% | 188.23% | 73.27% | 75.02% | -35.33% |
| Zoetis | -16.11% | -9.09% | -2.69% | 242.31% | 396.97% | 396.97% |
Performance & Financial Health Analysis: Ani Pharmaceuticals vs Zoetis
| Metric | ANIP | ZTS |
|---|---|---|
| Market Information | ||
| Market Cap | $1.90B | $65.30B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 1,023,840 | 4,111,510 |
| 90 Day Avg. Volume | 554,093 | 3,459,870 |
| Last Close | $90.61 | $167.10 |
| 52 Week Range | $52.50 - $91.02 | $139.70 - $200.33 |
| % from 52W High | -0.45% | -16.59% |
| All-Time High | $450.00 (May 29, 2000) | $249.27 (Dec 27, 2021) |
| % from All-Time High | -79.86% | -32.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.53% | 0.04% |
| Quarterly Earnings Growth | 0.53% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | -0.01% | 0.28% |
| Operating Margin (TTM) | 0.07% | 0.40% |
| Return on Equity (TTM) | -0.02% | 0.53% |
| Debt to Equity (MRQ) | 136.10 | 137.01 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $21.70 | $11.21 |
| Cash per Share (MRQ) | $11.12 | $3.28 |
| Operating Cash Flow (TTM) | $139.14M | $2.93B |
| Levered Free Cash Flow (TTM) | $89.39M | $2.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.11% |
| Last 12-Month Dividend | N/A | $1.86 |
Valuation & Enterprise Metrics Analysis: Ani Pharmaceuticals vs Zoetis
| Metric | ANIP | ZTS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 51.63 | 25.36 |
| Forward P/E | 15.82 | 23.24 |
| PEG Ratio | -0.14 | 23.24 |
| Price to Sales (TTM) | 2.54 | 6.96 |
| Price to Book (MRQ) | 4.03 | 13.14 |
| Market Capitalization | ||
| Market Capitalization | $1.90B | $65.30B |
| Enterprise Value | $2.19B | $70.67B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.93 | 7.53 |
| Enterprise to EBITDA | 20.97 | 17.91 |
| Risk & Other Metrics | ||
| Beta | 0.61 | 0.88 |
| Book Value per Share (MRQ) | $21.70 | $11.21 |
Financial Statements Comparison: Ani Pharmaceuticals vs Zoetis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ANIP | ZTS |
|---|---|---|
| Revenue/Sales | $197.12M | $2.22B |
| Cost of Goods Sold | $73.04M | $622.00M |
| Gross Profit | $124.09M | $1.60B |
| Research & Development | $10.56M | $157.00M |
| Operating Income (EBIT) | $14.10M | $846.00M |
| EBITDA | $37.19M | $991.00M |
| Pre-Tax Income | $19.99M | $810.00M |
| Income Tax | $4.31M | $179.00M |
| Net Income (Profit) | $15.68M | $631.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ANIP | ZTS |
|---|---|---|
| Cash & Equivalents | $149.80M | $1.72B |
| Total Current Assets | $536.29M | $5.88B |
| Total Current Liabilities | $201.82M | $3.39B |
| Long-Term Debt | $611.63M | $5.40B |
| Total Shareholders Equity | $443.47M | $4.66B |
| Retained Earnings | $-85.00M | $12.38B |
| Property, Plant & Equipment | N/A | $6.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ANIP | ZTS |
|---|---|---|
| Operating Cash Flow | $42.64M | $567.00M |
| Capital Expenditures | $-2.47M | N/A |
| Free Cash Flow | $15.15M | $438.00M |
| Debt Repayment | $-2.03M | N/A |
| Common Stock Repurchase | $-10.00M | $-443.00M |
Short Interest & Institutional Ownership Analysis
| Metric | ANIP | ZTS |
|---|---|---|
| Shares Short | 2.21M | 7.85M |
| Short Ratio | 7.17 | 2.67 |
| Short % of Float | 0.13% | 0.02% |
| Average Daily Volume (10 Day) | 1,023,840 | 4,111,510 |
| Average Daily Volume (90 Day) | 554,093 | 3,459,870 |
| Shares Outstanding | 21.11M | 448.47M |
| Float Shares | 16.57M | 442.37M |
| % Held by Insiders | 0.11% | 0.00% |
| % Held by Institutions | 0.99% | 0.98% |
Dividend Analysis & Yield Comparison: Ani Pharmaceuticals vs Zoetis
| Metric | ANIP | ZTS |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.86 |
| Last 12-Month Dividend Yield | N/A | 1.11% |
| 3-Year Avg Annual Dividend | N/A | $1.63 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $4.90 |
| Ex-Dividend Date | N/A | Apr 21, 2025 |